- Home
- WGS vs NEO Comparison
WGS vs NEO Comparison
Compare WGS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGS
- NEO
- Stock Information
- Founded
- WGS 2017
- NEO 2001
- Country
- WGS United States
- NEO United States
- Employees
- WGS N/A
- NEO N/A
- Industry
- WGS Retail: Computer Software & Peripheral Equipment
- NEO Precision Instruments
- Sector
- WGS Technology
- NEO Health Care
- Exchange
- WGS Nasdaq
- NEO Nasdaq
- Market Cap
- WGS 2.0B
- NEO 1.2B
- IPO Year
- WGS N/A
- NEO 1999
- Fundamental
- Price
- WGS $89.32
- NEO $9.52
- Analyst Decision
- WGS Strong Buy
- NEO Strong Buy
- Analyst Count
- WGS 5
- NEO 10
- Target Price
- WGS $82.60
- NEO $19.78
- AVG Volume (30 Days)
- WGS 1.2M
- NEO 1.6M
- Earning Date
- WGS 04-28-2025
- NEO 04-29-2025
- Dividend Yield
- WGS N/A
- NEO N/A
- EPS Growth
- WGS N/A
- NEO N/A
- EPS
- WGS N/A
- NEO N/A
- Revenue
- WGS $305,450,000.00
- NEO $660,566,000.00
- Revenue This Year
- WGS $18.58
- NEO $12.89
- Revenue Next Year
- WGS $17.65
- NEO $11.36
- P/E Ratio
- WGS N/A
- NEO N/A
- Revenue Growth
- WGS 50.79
- NEO 11.65
- 52 Week Low
- WGS $7.72
- NEO $8.98
- 52 Week High
- WGS $115.60
- NEO $19.11
- Technical
- Relative Strength Index (RSI)
- WGS 49.16
- NEO 37.87
- Support Level
- WGS $86.35
- NEO $9.00
- Resistance Level
- WGS $94.99
- NEO $10.95
- Average True Range (ATR)
- WGS 8.84
- NEO 0.83
- MACD
- WGS -1.76
- NEO 0.08
- Stochastic Oscillator
- WGS 15.13
- NEO 21.43
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.